JPMorgan Chase – Grifols, S.A. (NASDAQ:GRFS) Given Consensus Rating of “Hold” by Analysts
Shares of Grifols, S.A. (NASDAQ:GRFS) have been given a consensus recommendation of “Hold” by the nine research firms that are presently covering the stock, Marketbeat reports. Five analysts have rated the stock with a hold recommendation and four have issued a buy recommendation on the company. The average 12 month price objective among brokers that have issued ratings on the stock in the last year is $20.00.
A number of research analysts have recently commented on the company. Berenberg Bank restated a “buy” rating on shares of Grifols in a research note on Friday, October 30th. Morgan Stanley restated an “overweight” rating on shares of Grifols in a research note on Wednesday, January 13th. Zacks Investment Research upgraded Grifols from a “hold” rating to a “buy” rating and set a $20.00 target price for the company in a research note on Wednesday, February 3rd. Credit Suisse Group restated a “neutral” rating on shares of Grifols in a research note on Wednesday, January 20th. Finally, Barclays restated an “overweight” rating on shares of Grifols in a research note on Friday, January 22nd.
Large investors have recently made changes to their positions in the business. Hengistbury Investment Partners LLP purchased a new position in shares of Grifols in the third quarter worth $38,811,000. JPMorgan Chase & Co. raised its stake in shares of Grifols by 406.3% in the third quarter. JPMorgan Chase & Co. now owns 1,199,799 shares of the biotechnology company’s stock worth $20,169,000 after purchasing an additional 962,838 shares during the last quarter. First Trust Advisors LP raised its stake in shares of Grifols by 20.2% in the third quarter. First Trust Advisors LP now owns 3,749,065 shares of the biotechnology company’s stock worth $65,046,000 after purchasing an additional 629,650 shares during the last quarter. BlackRock Inc. raised its stake in shares of Grifols by 36.2% in the fourth quarter. BlackRock Inc. now owns 1,669,420 shares of the biotechnology company’s stock worth $30,784,000 after purchasing an additional 443,564 shares during the last quarter. Finally, CIBC Private Wealth Group LLC raised its stake in shares of Grifols by 143.0% in the third quarter. CIBC Private Wealth Group LLC now owns 716,538 shares of the biotechnology company’s stock worth $12,432,000 after purchasing an additional 421,677 shares during the last quarter. Institutional investors and hedge funds own 15.15% of the company’s stock.
Shares of GRFS stock opened at $17.23 on Monday. The firm has a market cap of $11.85 billion, a P/E ratio of 15.38, a P/E/G ratio of 1.30 and a beta of 0.59. Grifols has a fifty-two week low of $13.40 and a fifty-two week high of $25.73. The business’s 50 day moving average price is $18.79 and its 200-day moving average price is $18.10. The company has a debt-to-equity ratio of 0.95, a quick ratio of 1.33 and a current ratio of 2.93.
Grifols (NASDAQ:GRFS) last issued its quarterly earnings data on Thursday, November 5th. The biotechnology company reported $0.36 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.34 by $0.02. The firm had revenue of $1.52 billion for the quarter, compared to analyst estimates of $1.58 billion. Grifols had a return on equity of 10.65% and a net margin of 12.79%. As a group, equities analysts predict that Grifols will post 1.36 EPS for the current year.
Grifols Company Profile
Grifols, SA develops, manufactures, and distributes a range of biological medicines on plasma derived proteins worldwide. The company operates in five segments: Bioscience, Diagnostic, Hospital, Bio Supplies, and Others. The Bioscience segment manufactures plasma derivatives for therapeutic use; and sells and distributes end products.
Featured Story: Should I follow buy, hold and sell recommendations?
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to [email protected]